Verseon
Fremont, US · Delaware corporation
Verseon uses quantum physics-based modeling combined with AI to design novel small-molecule drug candidates for major human diseases. Its pipeline targets conditions including cardiovascular disease (anticoagulants), diabetic vision loss, multidrug-resistant cancers, and solid-tumor metastasis, with candidates ranging from preclinical to clinical stages.
AI & Machine LearningBiotechDeep Tech
Founders & leadership
AP
Adityo PrakashCEO
DK
David KitaCo-founder
EF
Eniko FodorCo-founder
Reported raises · per SEC filings
Form D private placements$25M disclosed across 7 rounds · 2005–2019
▶$101.4KraisedApr 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$101.4KraisedApr 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas HechtDirector
- Sangtae KimDirector
- Eniko FodorExecutive Officer, Director
- Adityo PrakashExecutive Officer, Director
- David KitaExecutive Officer
- Offering amount
- $101.4K
- Amount sold
- $101.4K
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$451KraisedMay 2015 · 10 investors · PharmaceuticalsRule 506(b)
▶$451KraisedMay 2015 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Adityo PrakashExecutive Officer, Director
- Eniko FodorExecutive Officer, Director
- David KitaExecutive Officer
- Offering amount
- $451K
- Amount sold
- $451K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.8MraisedMay 2015 · 5 investors · PharmaceuticalsRule 506(b)
▶$11.8MraisedMay 2015 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eniko FodorExecutive Officer, Director
- Adityo PrakashExecutive Officer, Director
- David KitaExecutive Officer
- Offering amount
- $11.8M
- Amount sold
- $11.8M
- First sale
- Sep 2009
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.5MraisedMay 2015 · 22 investors · PharmaceuticalsRule 506(b)
▶$6.5MraisedMay 2015 · 22 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David KitaExecutive Officer
- Adityo PrakashExecutive Officer, Director
- Eniko FodorExecutive Officer, Director
- Offering amount
- $6.5M
- Amount sold
- $6.5M
- First sale
- Oct 2005
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$69.8KraisedMay 2015 · 5 investors · PharmaceuticalsRule 506(b)
▶$69.8KraisedMay 2015 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David KitaExecutive Officer
- Eniko FodorExecutive Officer, Director
- Adityo PrakashExecutive Officer, Director
- Offering amount
- $69.8K
- Amount sold
- $69.8K
- First sale
- Jun 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$259.6KraisedMay 2015 · 13 investors · PharmaceuticalsRule 506(b)
▶$259.6KraisedMay 2015 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David KitaExecutive Officer
- Adityo PrakashExecutive Officer, Director
- Eniko FodorExecutive Officer, Director
- Offering amount
- $259.6K
- Amount sold
- $259.6K
- First sale
- Sep 2010
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedMay 2015 · 28 investors · PharmaceuticalsRule 506(b)
▶$5.8MraisedMay 2015 · 28 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Adityo PrakashExecutive Officer, Director
- David KitaExecutive Officer
- Eniko FodorExecutive Officer, Director
- Offering amount
- $5.8M
- Amount sold
- $5.8M
- First sale
- Feb 2008
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapRegeneron NASDAQ: REGN www.regeneron.com11 shared keywordsRegeneron is a biopharmaceutical company that develops medicines ranging from biologics to genetic medicines for people with serious diseases across areas such as metabolic disease, ophthalmology, and rare diseases. It runs research and development programs and clinical trials aimed at treating conditions including generalized myasthenia gravis.
Starton Therapeutics7 shared keywordsStarton Therapeutics is a clinical-stage biotechnology company that reformulates FDA-approved drugs using proprietary controlled delivery systems to improve their pharmacokinetic profiles. It develops subcutaneous, oral, and transdermal delivery methods aimed at achieving better outcomes in existing or new indications.
Companies competing with Verseon for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Verseon do?
- Verseon uses quantum physics-based modeling combined with AI to design novel small-molecule drug candidates for major human diseases. Its pipeline targets conditions including cardiovascular disease (anticoagulants), diabetic vision loss, multidrug-resistant cancers, and solid-tumor metastasis, with candidates ranging from preclinical to clinical stages.
- Who founded Verseon?
- Verseon was founded by Adityo Prakash, David Kita, Eniko Fodor.
- How much funding has Verseon raised?
- Verseon has disclosed $25M raised across 7 rounds.
- Where is Verseon headquartered?
- Verseon is headquartered in Fremont, US.